After decades of largely unmet needs, new developments offer a cautiously optimistic outlook for those battling Alzheimer’s disease, a condition affecting over 55 million peopel worldwide[[1]]. recent advancements include the first treatments demonstrating a capacity to slow disease progression, alongside a potentially game-changing blood test for earlier diagnosis. Though, the clinical benefits and cost-effectiveness of these innovations are now the subject of intense debate among medical professionals and healthcare systems globally, as detailed in the following report.
After decades of unsuccessful research, two new drugs and a groundbreaking blood test have recently offered patients with Alzheimer’s disease a glimmer of hope in confronting the debilitating condition. However, questions remain about just how effective these advancements will be.
An effective path to treating Alzheimer’s remains elusive, as the disease accounts for approximately 70% of dementia cases worldwide and is a leading cause of death among seniors. This makes finding solutions a critical public health priority.
Here’s what you need to know about the latest developments in diagnosing, preventing, and treating this disease.
How Effective Are the New Drugs?
Billions of dollars have been spent attempting to find a cure for Alzheimer’s over the decades, but those efforts have repeatedly fallen short – until recently.
Donanemab, from Eli Lilly, and lecanemab, from Eisai and Biogen, are the first treatments to demonstrate a significant ability to slow the progression of Alzheimer’s disease.
However, these expensive treatments have limited effectiveness and are only for patients in the early stages of the disease. Serious side effects, including potentially fatal brain bleeds, are also possible.
This has sparked debate over whether the benefits of these drugs outweigh the risks, leading to differing positions from national health authorities.
Lecanemab, marketed as Leqembi, has been approved for use in many countries, including the United States, but French authorities advised its national health insurance system against covering the cost.
A similar decision was made by the National Institute for Health and Care Excellence (NICE) in the United Kingdom, which stated this year that the two new Alzheimer’s drugs do not offer enough benefit for their high price.
What About Early Diagnosis?
Another area of ongoing Alzheimer’s research, also marked by growing divisions between Europe and the United States, centers on how the disease is diagnosed.
Traditionally, diagnosing Alzheimer’s required an invasive and costly spinal tap, potentially excluding some at-risk patients. However, a recently developed simple blood test can detect “biomarkers” of the disease.
The U.S. Food and Drug Administration authorized the test in May, but Europe has yet to approve any Alzheimer’s-specific blood test. One such test is the subject of a recently launched national clinical trial in Britain.
The question remains: will a blood test alone be sufficient to confidently diagnose the disease?
Last year, the Alzheimer’s Association changed its criteria to state that “biomarkers alone are sufficient.” However, most specialists in Europe believe a comprehensive clinical evaluation remains necessary to confirm the cognitive and functional decline in an individual.
“Many patients with abnormal biomarkers never develop dementia,” said Dutch neurologist Edo Richard. He is also skeptical about the two new Alzheimer’s drugs.
These two issues are interconnected, as proponents of the new drugs believe the ability to diagnose the disease before noticeable symptoms appear could enhance treatment effectiveness.
Can Alzheimer’s Be Prevented?
One area of agreement focuses on identifying factors that increase a person’s risk of developing Alzheimer’s and dementia in general.
According to a review published in The Lancet last year, nearly half of cases are linked to factors such as obesity, smoking, alcohol consumption, physical inactivity, and hearing loss.
Research is increasing to determine whether programs encouraging people to exercise and eat a healthy diet are effective in combating Alzheimer’s.
However, rigorous randomized controlled trials targeting these factors have shown “limited or no effect on cognitive decline and dementia,” according to Richard.
A recent study published in JAMA found that cognitive decline slowed slightly in Alzheimer’s patients after they received two years of intensive support aimed at improving their health.
For those living with Alzheimer’s and their families, this level of progress may not seem substantial, as French epidemiologist Cécilia Samieri acknowledged at a conference this month.
However, compared to where things stood a few years ago, Samieri said, “it is already a huge achievement.”
She added that she believes trials lasting 10 to 15 years are needed to truly demonstrate the effectiveness of these interventions against slowly developing diseases like Alzheimer’s.
